CIK 0001672619
ELVN Enliven Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Dec 31, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Signals
Open-market buys and sells at Enliven Therapeutics, Inc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 17Weak | sell10b5-1 | Hohl Benjamin CHIEF FINANCIAL OFFICER | $94k | 4,250 | -127% | - | |
| 18Weak | sell10b5-1 | Hohl Benjamin CHIEF FINANCIAL OFFICER | $131k | 5,250 | -100% | - | |
| 34Weak | sell 610b5-1 | Hohl Benjamin CHIEF FINANCIAL OFFICER | $178k | 6,250 | -100% | - | |
| 15Weak | sell 610b5-1 | Collins Helen Louise CHIEF MEDICAL OFFICER | $24k | 816 | -100% | - | |
| 16Weak | sell 610b5-1 | Heyman Richard A. director | $47k | 1,570 | -1% | - | |
| 22Weak | sell 610b5-1 | Hohl Benjamin CHIEF FINANCIAL OFFICER | $24k | 814 | -100% | - | |
| 25Weak | sell 610b5-1 | Kintz Samuel PRESIDENT AND CEO | $28k | 924 | -0% | - | |
| 15Weak | sell 610b5-1 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | $25k | 847 | -0% | - | |
| 15Weak | sell 610b5-1 | Patel Anish CHIEF OPERATING OFFICER | $21k | 716 | -0% | - | |
| 16Weak | sell 610b5-1 | Heyman Richard A. director | $35k | 1,270 | -1% | - |
Transactions
The last 26 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 27, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | MOption exercise Common Stock10b5-1 | +3,350 | $2.48 | $8,308 | 3,350 | Dec 31, 2024 |
| Dec 27, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -3,350 | $22.15 | $74k | 0 | Dec 31, 2024 |
| Dec 30, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | MOption exercise Common Stock10b5-1 | +900 | $2.48 | $2,232 | 900 | Dec 31, 2024 |
| Dec 30, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -900 | $22.51 | $20k | 0 | Dec 31, 2024 |
| Dec 27, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,350 | $0.00 | $0 | 165,206 | Dec 31, 2024 |
| Dec 30, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | MOption exercise Stock Option (right to buy)derivative10b5-1 | -900 | $0.00 | $0 | 164,306 | Dec 31, 2024 |
| Nov 27, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | MOption exercise Common Stock10b5-1 | +5,250 | $2.48 | $13k | 5,250 | Dec 2, 2024 |
| Nov 27, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -4,250 | $24.78 | $105k | 1,000 | Dec 2, 2024 |
| Nov 27, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,000 | $25.38 | $25k | 0 | Dec 2, 2024 |
| Nov 27, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,250 | $0.00 | $0 | 168,556 | Dec 2, 2024 |
| Oct 28, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | MOption exercise Common Stock10b5-1 | +6,250 | $2.48 | $16k | 6,250 | Oct 30, 2024 |
| Oct 28, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -5,600 | $28.49 | $160k | 650 | Oct 30, 2024 |
| Oct 28, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -650 | $29.11 | $19k | 0 | Oct 30, 2024 |
| Oct 28, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | MOption exercise Stock Option (right to buy)derivative10b5-1 | -6,250 | $0.00 | $0 | 173,806 | Oct 30, 2024 |
| Oct 18, 2024 | Collins Helen Louise CHIEF MEDICAL OFFICER | MOption exercise Common Stock10b5-1 | +816 | $2.48 | $2,024 | 816 | Oct 22, 2024 |
| Oct 18, 2024 | Heyman Richard A. director | SOpen-market sale Common Stock10b5-1 | -817 | $30.00 | $25k | 123,673 | Oct 22, 2024 |
| Oct 18, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | MOption exercise Common Stock10b5-1 | +814 | $2.48 | $2,019 | 814 | Oct 22, 2024 |
| Oct 18, 2024 | Kintz Samuel PRESIDENT AND CEO | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -924 | $30.00 | $28k | 1,002,892 | Oct 22, 2024 |
| Oct 18, 2024 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -847 | $30.00 | $25k | 1,015,188 | Oct 22, 2024 |
| Oct 18, 2024 | Patel Anish CHIEF OPERATING OFFICER | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -716 | $30.00 | $21k | 343,311 | Oct 22, 2024 |
| Oct 18, 2024 | Collins Helen Louise CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -816 | $30.00 | $24k | 0 | Oct 22, 2024 |
| Oct 18, 2024 | Heyman Richard A. director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -753 | $30.00 | $23k | 27,165 | Oct 22, 2024 |
| Oct 18, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -814 | $30.00 | $24k | 0 | Oct 22, 2024 |
| Oct 18, 2024 | Collins Helen Louise CHIEF MEDICAL OFFICER | MOption exercise Stock Option (right to buy)derivative10b5-1 | -816 | $0.00 | $0 | 266,268 | Oct 22, 2024 |
| Oct 18, 2024 | Hohl Benjamin CHIEF FINANCIAL OFFICER | MOption exercise Stock Option (right to buy)derivative10b5-1 | -814 | $0.00 | $0 | 180,056 | Oct 22, 2024 |
| Oct 15, 2024 | Heyman Richard A. director | SOpen-market sale Common Stock10b5-1 | -1,270 | $27.67 | $35k | 124,490 | Oct 17, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Collins Helen LouiseCHIEF MEDICAL OFFICER
- Heyman Richard A.director
- Hohl BenjaminCHIEF FINANCIAL OFFICER
- Kintz SamuelPRESIDENT AND CEO
- Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
- Patel AnishCHIEF OPERATING OFFICER
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.